Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9753360 | 0.92 | GPR84 (0.37) | GPR84FFAR1HCAR2HPGDMEN1 | |
| SCHEMBL29061782 | 0.92 | GPR84 (0.37) | GPR84FFAR1HCAR2HPGDMEN1 | |
| SCHEMBL29061780 | 0.92 | GPR84 (0.37) | GPR84FFAR1HCAR2HPGDMEN1 | |
| SCHEMBL8935620 | 0.90 | GPR84 (0.40) | GPR84FFAR1HCAR2HPGDMEN1 | |
| SCHEMBL455822 | 0.90 | GPR84 (0.40) | GPR84FFAR1HCAR2HPGDMEN1 | |
| SCHEMBL17373019 | 0.83 | TERT (0.42) | PPARGPPARAATMACLYRECQL | |
| SCHEMBL3615672 | 0.83 | CPT2 (0.32) | PPARGPPARACPT2ACLY | |
| SCHEMBL17821128 | 0.81 | GPR84 (0.31) | GPR84FFAR1ALDH1A1 | |
| SCHEMBL18007391 | 0.81 | GPR84 (0.31) | GPR84FFAR1ALDH1A1 | |
| SCHEMBL10933728 | 0.81 | CA2 (0.36) | GPR84FFAR1ALDH1A1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149439-B2 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2015-10-06 | — | — | US | claimed |
| WO-2014029953-A1 | HOT MELT EXTRUDED (HME) PHARMACEUTICAL COMPOSITION OF CINACALCET | CIPLA LIMITED (IN) | 2014-02-27 | — | — | WO | claimed |
| US-8168228-B2 | Oral micropellets containing an antibiotic having an inner coating of a cellulose polymer (not enteric)and an outer coating of an enteric coating polymer; particle size of 100 to 650 mu m.; lack of bitter taste; fast dissolution; increased antibiotic bioavailability compared pellets having a matrix | SANDOZ AG (CH) | 2012-05-01 | — | — | US | claimed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | claimed |
| US-20100173921-A1 | Antiretroviral Solid Oral Composition | CIPLA LIMITED (IN) | 2010-07-08 | — | — | US | claimed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | claimed |
| EP-1680088-B1 | Taste-masked formulation comprising clarithromycin | SANDOZ AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2008017867-A2 | ANTIRETROVIRAL SOLID ORAL COMPOSITION WITH AT LEAST ONE WATER INSOLUBLE POLYMER | CIPLA LIMITED (IN) | 2008-02-14 | — | — | WO | claimed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | claimed |
| US-20070134344-A1 | Antibiotic compositions | SANDOZ AG (CH) | 2007-06-14 | — | — | US | claimed |
| US-20070048379-A1 | Valproate tablet | GUO MINTONG | 2007-03-01 | — | — | US | claimed |
| WO-2006102446-A2 | MULTI-PARTICULATE, MODIFIED-RELEASED COLONIC COMPOSITION | SANDOZ AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-20060210631-A1 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2006-09-21 | — | — | US | claimed |
| EP-1680088-A1 | ANTIBIOTIC COMPOSITIONS | Sandoz AG (CH) | 2006-07-19 | — | — | EP | claimed |
| US-20050181052-A1 | Lansoprazole microtablets | PATEL SATISHKUMAR A (US) | 2005-08-18 | — | — | US | claimed |
| WO-2005039536-A1 | ANTIBIOTIC COMPOSITIONS | SANDOZ AG (CH) | 2005-05-06 | — | — | WO | claimed |
| US-20050084541-A1 | Antibiotic compositions | SANDOZ, AG (CH) | 2005-04-21 | — | — | US | claimed |
| EP-0951905-A2 | Pharmaceutical compositions for programmed therapeutical coverage | APR APPLIED PHARMA RESEARCH S.A. (CH) | 1999-10-27 | — | — | EP | claimed |
| EP-4081215-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-20 | — | — | EP | disclosed |
| US-4743673-A | MEDICAL EQUIPMENT, DRUG DELIVERY, ANTIFRICTION | TYNDALE PLAINS-HUNTER, LTD. (US) | 1988-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK2, CDK9, CDK1 | GPR84 2070/4885FFAR1 1925/4885ALDH1A1 1497/4885 |
| US-20070048379-A1 | Valproate tablet | CACNA1A, SUCLG2, CACNA1G | GPR84 3013/4885FFAR1 2026/4885ALDH1A1 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.